| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Zuzana Justinova | Q30225591 |
| Enric I. Canela | Q52339029 | ||
| Sergi Ferré | Q39025293 | ||
| Rafael Franco | Q40238726 | ||
| P2093 | author name string | Carme Lluís | |
| Gemma Navarro | |||
| Steven R Goldberg | |||
| Marco Orru | |||
| César Quiroz | |||
| P2860 | cites work | Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease | Q57708611 |
| D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain | Q72244610 | ||
| Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study | Q81630893 | ||
| Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers | Q24304896 | ||
| Dopamine D2 receptors form higher order oligomers at physiological expression levels | Q24318766 | ||
| Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization | Q24323514 | ||
| D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum | Q24338488 | ||
| Cannabinoid receptor localization in brain | Q24558751 | ||
| Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes | Q24563287 | ||
| Building a new conceptual framework for receptor heteromers | Q24644975 | ||
| Identification of a serotonin/glutamate receptor complex implicated in psychosis | Q24655484 | ||
| Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers | Q24657821 | ||
| Looking for the role of cannabinoid receptor heteromers in striatal function | Q24658338 | ||
| Adenosine A2A receptors and basal ganglia physiology | Q24669783 | ||
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists | Q28190150 | ||
| International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors | Q28209239 | ||
| Cannabinoid signalling | Q28267949 | ||
| Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 | ||
| Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 | ||
| Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice | Q28343324 | ||
| Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice | Q28469322 | ||
| Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids | Q28571785 | ||
| Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus | Q28579094 | ||
| The molecular logic of endocannabinoid signalling | Q29615356 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain | Q30047898 | ||
| Transient adenosine efflux in the rat caudate-putamen | Q30445389 | ||
| Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens | Q30499463 | ||
| Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. | Q31813503 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| Behavioral effects of cannabinoid agents in animals | Q33914022 | ||
| Nucleus accumbens shell and core dopamine: differential role in behavior and addiction | Q34160295 | ||
| Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration | Q34191271 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Modulation of transmitter release via presynaptic cannabinoid receptors | Q34430714 | ||
| Astrocytic purinergic signaling coordinates synaptic networks | Q34457580 | ||
| Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase | Q34491915 | ||
| Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study | Q34524477 | ||
| D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor | Q44666474 | ||
| Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. | Q44770106 | ||
| Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure | Q44792331 | ||
| Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice | Q44909893 | ||
| Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation | Q45138309 | ||
| Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. | Q45922072 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. | Q46670474 | ||
| Depression and anxiety with rimonabant | Q46894221 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. | Q48837860 | ||
| Coordinated expression of dopamine receptors in neostriatal medium spiny neurons | Q48890601 | ||
| Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. | Q54707901 | ||
| Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. | Q55035681 | ||
| Circuits and circuit disorders of the basal ganglia | Q34599488 | ||
| Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis | Q34631075 | ||
| Detection of heteromerization of more than two proteins by sequential BRET-FRET. | Q34790164 | ||
| Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function | Q35603262 | ||
| DARPP-32: an integrator of neurotransmission | Q35639141 | ||
| Astrocytic control of glutamatergic activity: astrocytes as stars of the show | Q35947530 | ||
| Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. | Q36087867 | ||
| Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. | Q36119168 | ||
| Endocannabinoid signaling system and brain reward: emphasis on dopamine | Q36152336 | ||
| Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step | Q36300113 | ||
| Neural mechanisms of drug reinforcement | Q36330262 | ||
| Endocannabinoid system involvement in brain reward processes related to drug abuse | Q36357182 | ||
| An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors | Q36713961 | ||
| Endocannabinoids and synaptic function in the CNS. | Q36778581 | ||
| Functional relevance of neurotransmitter receptor heteromers in the central nervous system. | Q36907702 | ||
| Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials | Q37005419 | ||
| Allosteric modulation of heterodimeric G-protein-coupled receptors. | Q37005570 | ||
| Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders | Q37067424 | ||
| GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors | Q37176918 | ||
| The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake | Q37376376 | ||
| Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. | Q39817865 | ||
| Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. | Q39831177 | ||
| Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors | Q40516448 | ||
| Neurobehavioural mechanisms of reward and motivation. | Q41049144 | ||
| Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization | Q41130757 | ||
| Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia | Q41620234 | ||
| Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia | Q41624006 | ||
| Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia | Q42486484 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Actions of adenosine A 2A receptors on synaptic connections of spiny projection neurons in the neostriatal inhibitory network. | Q42524706 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens | Q44345871 | ||
| Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
| Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. | Q44348080 | ||
| Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer | Q44559398 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| striatum | Q1319792 | ||
| P304 | page(s) | 443-53 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Adenosine-cannabinoid receptor interactions. Implications for striatal function | |
| P478 | volume | 160 |
| Q36057652 | A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease |
| Q28728678 | A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation |
| Q85848881 | Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two |
| Q35056410 | Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function |
| Q57778947 | Adenosine A2A Receptors: Localization and Function |
| Q90399476 | Altered Cingulate Cortex Functional Connectivity in Normal Aging and Mild Cognitive Impairment |
| Q64087605 | Altered structural and causal connectivity in frontal lobe epilepsy |
| Q33687719 | Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia |
| Q90480148 | Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome |
| Q34676610 | Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? |
| Q34248777 | Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output |
| Q37842745 | Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance |
| Q37678864 | Cannabinoid, melanocortin and opioid receptor expression on DRD1 and DRD2 subpopulations in rat striatum |
| Q21090468 | Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far |
| Q27336451 | Cannabinoids and Epilepsy. |
| Q45368915 | Cocaine and Caffeine Effects on the Conditioned Place Preference Test: Concomitant Changes on Early Genes within the Mouse Prefrontal Cortex and Nucleus Accumbens |
| Q40012358 | Combined Effects of Simultaneous Exposure to Caffeine and Cocaine in the Mouse Striatum |
| Q36176480 | Combined effects of THC and caffeine on working memory in rats. |
| Q92886078 | Control of glutamate release by complexes of adenosine and cannabinoid receptors |
| Q58791740 | DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests |
| Q92667174 | Discriminating schizophrenia using recurrent neural network applied on time courses of multi-site FMRI data |
| Q42575093 | Dissecting striatal adenosine-cannabinoid receptor interactions. New clues from rats over-expressing adenosine A2A receptors. |
| Q48807094 | Effects of A₂A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats |
| Q39619821 | Functional atlas of the awake rat brain: A neuroimaging study of rat brain specialization and integration. |
| Q38210280 | G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system. |
| Q30454318 | Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses |
| Q35053193 | Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q35489240 | Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. |
| Q35166968 | Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum |
| Q38636791 | Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure |
| Q35039222 | Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of corticostriatal glutamatergic transmission |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q37284060 | Purinergic signaling and energy homeostasis in psychiatric disorders |
| Q35046370 | Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist |
| Q35962060 | Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain |
| Q39454293 | Role of G Protein-Coupled Receptors in the Regulation of Structural Plasticity and Cognitive Function |
| Q48112379 | Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia |
| Q39013000 | Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum. |
| Q50917064 | Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors. |
| Q45864839 | The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals |
| Q42495608 | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. |
| Q24620262 | Themed issue: cannabinoids |
| Q48873079 | Toward a model of retrograde regulation of striatal synaptic depression. |
Search more.